Asset Details
Do you wish to reserve the book?
Development of breakthrough bleeding model of combined‐oral contraceptives utilizing model‐based meta‐analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of breakthrough bleeding model of combined‐oral contraceptives utilizing model‐based meta‐analysis
Do you wish to request the book?
Development of breakthrough bleeding model of combined‐oral contraceptives utilizing model‐based meta‐analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of breakthrough bleeding model of combined‐oral contraceptives utilizing model‐based meta‐analysis
2024
Overview
Breakthrough bleeding (BTB) is a common side effect of hormonal contraception and is thought to impact adherence to combined oral contraceptives (COCs) but respective dose–response relationships are not yet fully understood. Therefore, the objective of this model‐based meta‐analysis (MBMA) was to establish dose–response for COCs containing different progestin/EE combinations using BTB as the pharmacodynamic endpoint. Data from 25 studies containing BTB information of 4 progestins (desogestrel, drospirenone, gestodene, and levonorgestrel) in combination with ethinyl estradiol (EE) at various dose levels was used for this analysis. The results of our MBMA show that BTB is significantly increased upon initiation of COC use but subsides over time. The time needed for BTB to return to baseline depends on the EE dose and differs marginally between progestins during the initial months of use at the same EE dose. BTB typically returns to baseline within 3 months at the highest (30 μg) dose, whereas it can take significantly longer to reestablish a regular bleeding pattern at lower EE doses (15 and 20 μg), irrespective of the progestin used. The dose–response relationships established for BTB across different progestin/EE combinations can now be used to support the selection of optimal COC dosing/treatment regimens and serve as the scientific basis for evaluating the impact of clinically relevant factors, including drug–drug interactions and demographics, on BTB.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Contraceptives, Oral, Combined - administration & dosage
/ Contraceptives, Oral, Combined - adverse effects
/ Desogestrel - administration & dosage
/ Desogestrel - adverse effects
/ Dose-Response Relationship, Drug
/ Ethinyl Estradiol - administration & dosage
/ Ethinyl Estradiol - adverse effects
/ Female
/ Humans
/ Levonorgestrel - administration & dosage
/ Levonorgestrel - adverse effects
/ Norpregnenes - administration & dosage
/ Norpregnenes - adverse effects
/ Progestins - administration & dosage
